108 citations
,
January 2010 in “International Journal of Andrology” Weak endocrine disruptors in mixtures can have significant effects and should be considered in risk assessments.
March 2005 in “European Urology Supplements” July 2025 in “Journal of Investigative Dermatology”
November 2023 in “Dermatology and Therapy” Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
11 citations
,
August 2014 in “Current Urology Reports” Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
9 citations
,
December 2009 in “Cancer Research” Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
6 citations
,
September 2022 in “Frontiers in pharmacology” Epimedium extract helps increase skin pigmentation and could be a new treatment for conditions with reduced pigmentation.
Baricitinib may not always prevent relapse in alopecia areata.
1 citations
,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
1 citations
,
November 2024 in “Archives of Dermatological Research”
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
3 citations
,
January 2003 in “Synthetic Communications” Scientists made two new chemicals that might help treat diseases caused by male hormones.
2 citations
,
May 2016 in “Journal of Clinical Oncology” Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
May 2018 in “Journal of Clinical Oncology” The treatment is safe and shows promise for metastatic breast cancer.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
February 2024 in “International Journal of Pharmaceutics” A new hair loss treatment combining minoxidil and cedrol improves hair growth and reduces side effects.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
5-ARI therapy may help prevent prostate cancer progression.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
January 2023 in “Pharmaceutics” AA–TF#15 significantly promotes hair regrowth and could be an effective treatment for androgenic alopecia.